Stephen C Harrison

This inventor holds 18 USPTO granted patents and 2 published patent applications, plus 5 CIPO patents and 5 EPO patents, primarily in Vaccine Development. Top assignees: Children's Medical Center Corporation, Beth Israel Deaconess Medical Center, Inc., Duke University. Active years: 2003-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephen C Harrison. Retrieved from https://idiyas.com/inventor/stephen-c-harrison

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 2)

% Patents Active = 83.3

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 13(Granted Patents)

Location History:

Cambridge, MA (US) (2003 - 2014)
Boston, MA (US) (2018 - 2021)
Brighton, MA (US) (2014 - 2022)

Company Filing History:

16 out of 1,074

Children's Medical Center Corporation

patents

5 out of 539

Beth Israel Deaconess Medical Center, Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

US Government as Represented by the Secretary of the Army

patents

7. 1 out of 1,268

Dana-Farber-Cancer Institute Inc.

patents

8. 1 out of 140

Howard Hughes Medical Institute

patents

9. 1 out of 5,515

Leland Stanford Junior University

where one patent can have more than one assignee

Years Active: 2003-2022

Loading Chart...

Areas of Expertise:

HIV-1 Vaccine

Immunogens

Rotavirus

Dengue Virus

Neutralizing Antibodies

Chimeric Proteins

Human Papillomavirus

Biochemical Stabilization

B Cell Lineage

Vaccine Compositions

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11229696 - Biochemically stabilized HIV-1 Env trimer vaccine (2022-01-25),

2. 11191823 - Compositions and methods for treating arenavirus infection (2021-12-07),

3. 11053285 - Nucleic acids encoding human immunodeficiency virus type 1 (HIV-1) N-terminal deleted gp120 immunogens and methods of use (2021-07-06),

4. 10835599 - Methods to identify prime and boost immunogens for use in a B cell lineage-based vaccination protocol (2020-11-17),

5. 10653770 - Biochemically stabilized HIV-1 Env trimer vaccine (2020-05-19),

6. 10463729 - Biochemically stabilized HIV-1 env trimer vaccine (2019-11-05),

7. 10307478 - Biochemically stabilized HIV-1 Env trimer vaccine (2019-06-04),

8. 10192025 - Rotavirus particles with chimeric surface proteins (2019-01-29),

9. 10092638 - GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus (2018-10-09),

10. 10040826 - Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens (2018-08-07),

11. 9950060 - Biochemically stabilized HIV-1 Env trimer vaccine (2018-04-24),

12. 9718873 - Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin (2017-08-01),

13. 9707289 - Biochemically stabilized HIV-1 ENV trimer vaccine (2017-07-18),

14. 8741310 - Fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies (2014-06-03),

15. 8685411 - Rotavirus antigens (2014-04-01),

Title: The Innovative Journey of Stephen C. Harrison

Introduction

Stephen C. Harrison, a prominent inventor based in Brighton, MA, has made significant contributions to the field of biomedical research. With a remarkable portfolio of 18 patents, Harrison has dedicated his career to finding solutions to some of the most pressing health challenges, particularly in the realm of viral infections.

Latest Patents

Among his latest inventions is a biochemically stabilized HIV-1 Env trimer vaccine, which focuses on offering protection against HIV-1 by stabilizing trimers of clade A and clade C strains. This pioneering work also embraces the development of broadly neutralizing antisera against HIV-1, providing methods of production, as well as innovative strategies for treating and preventing HIV infections. Additionally, Harrison has created compositions and methods targeted at treating arenavirus infections. This invention emphasizes the importance of using agents that inhibit the binding of arenavirus glycoprotein 1 (GP1) polypeptide to transferrin receptor 1 (TfR1), alongside methods for identifying therapeutic agents that target this crucial receptor-binding site.

Career Highlights

Stephen C. Harrison's career is marked by significant milestones, having worked with esteemed institutions such as Children's Medical Center Corporation and Duke University. His experience in these organizations has enriched his insights into medical research and innovation, fostering an environment conducive to groundbreaking discoveries.

Collaborations

Throughout his career, Harrison has collaborated with notable individuals in the field, including Bing Chen and Michael Scott Seaman. These partnerships have been instrumental in advancing his research and contributing to his impressive array of patents.

Conclusion

In conclusion, Stephen C. Harrison stands as a vital figure in the landscape of biomedical innovation. His dedication to developing vaccines and treatment methods for viral infections not only showcases his ingenuity but also his commitment to improving public health outcomes. With a continued focus on research and collaboration, Harrison’s contributions are likely to resonate in the medical community for years to come.

Profile summary based on public USPTO records.